Ozonized autohaemotransfusion and fibrinolytic balance in peripheral arterial occlusive disease.
The acute effects of a major ozonized autohaemotransfusion on blood fibrinolytic capacity were evaluated in 20 subjects affected by peripheral arterial occlusive disease (PAOD). The parameters examined were tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1). In subjects not previously submitted to autohaemotransfusion ('unaccustomed' subjects), whether they were PAOD patients or healthy volunteers, the PAI-1/t-PA ratio in the blood samples taken 15 min before the autohaemotransfusion was higher (P < or = 0.05) than at baseline. These changes were independent of the presence of ozone in the autohaemotransfusion blood. Values in both healthy and PAOD-affected individuals were again at baseline 120 min after the end of autohaemotransfusion. In PAOD patients and in healthy subjects previously submitted to several autohaemotransfusions ('accustomed' subjects), the PAI-1/t-PA ratio did not significantly change before, during and after an additional autohaemotransfusion. The results (the increased heart rate and epinephrine and norepinephrine urinary excretion only in non-accustomed subjects) suggest that the acute fibrinolytic imbalance is caused by the apprehensive state produced by the procedure in unaccustomed subjects. Autohaemotransfusion with ozonized blood per se does not significantly influence the fibrinolytic balance.
Coppola
L
L
Department of Geriatric Medicine and Metabolic Diseases, Policlinico Universitario, Piazza Miraglia, Napoli, Italy. LudovicoCOPPOLA@unina2.it
Lettieri
B
B
Cozzolino
D
D
Luongo
C
C
Sammartino
A
A
Guastafierro
S
S
Coppola
A
A
Mastrolorenzo
L
L
Gombos
G
G
D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000097:blood*; D001804:Blood Transfusion, Autologous / Q000009:adverse effects*; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010126:Ozone / Q000494:pharmacology*; D016491:Peripheral Vascular Diseases / Q000097:blood*; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D013315:Stress, Psychological / Q000097:blood / Q000503:physiopathology; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000187:drug effects
D017395:Plasminogen Activator Inhibitor 1; D010126:Ozone; D010959:Tissue Plasminogen Activator